Equities
  • Price (EUR)42.12
  • Today's Change2.39 / 6.02%
  • Shares traded4.61k
  • 1 Year change+125.60%
  • Beta2.0357
Data delayed at least 15 minutes, as of Jun 27 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

  • Revenue in USD (TTM)1.78bn
  • Net income in USD164.40m
  • Incorporated2021
  • Employees1.64k
  • Location
    Hims & Hers Health Inc2269 Chestnut St, #523SAN FRANCISCO 94123United StatesUSA
  • Phone+1 (415) 851-0195
  • Fax+1 (302) 655-5049
  • Websitehttps://www.forhims.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HIMS:NYQ since
announced
Transaction
value
Zava Global GmbhAnnounced03 Jun 202503 Jun 2025Announced-12.19%--
C S Bio Co-Peptide FacilityDeal completed01 Feb 202501 Feb 2025Deal completed33.72%--
Data delayed at least 15 minutes, as of Jun 30 2025 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.